-
公开(公告)号：US20160376244A1
公开(公告)日：2016-12-29
申请号：US15190642
申请日：2016-06-23
发明人： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC分类号： C07D265/22 , C07D413/06 , C07D491/107 , C07D413/04 , C07F7/02 , C07D471/04 , C07D413/14 , C07D413/10
CPC分类号： C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
摘要翻译： 其中每个符号如所附的说明中所定义。
-
2.发明申请公开(公告)号：US20190248776A1
公开(公告)日：2019-08-15
申请号：US16394762
申请日：2019-04-25
发明人： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC分类号： C07D413/14 , C07D491/107 , C07D471/04 , C07D417/06 , C07D413/10 , C07D413/06 , C07D265/22 , C07F7/02 , C07D413/04 , C07F7/08 , A61P25/28 , C07D417/10
CPC分类号： C07D413/14 , A61P25/28 , C07B2200/07 , C07D265/22 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US20220098180A1
公开(公告)日：2022-03-31
申请号：US17426971
申请日：2020-01-29
发明人： Masahiro ITO , Takeshi YAMAMOTO , Keiko KAKEGAWA , Hideyuki SUGIYAMA , Tohru MIYAZAKI , Yasuyoshi ARIKAWA , Tomohiro OKAWA , Jinichi YONEMORI , Osamu KUBO , Akinori TOITA , Takuto KOJIMA , Fumiaki KIKUCHI , Minoru SASAKI , Misaki HOMMA , Yasuhiro IMAEDA , Hironobu MAEZAKI , Shiinobu SASAKI , Ayumu SATO , Hirotaka KAMITANI , Yasutomi ASANO , Hironori KOKUBO , Masato YOSHIKAWA
IPC分类号： C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
摘要： The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US20210139491A1
公开(公告)日：2021-05-13
申请号：US16622632
申请日：2018-06-19
发明人： Kazuaki TAKAMI , Masaki SETO , Shinobu SASAKI , Haruhi ANDO , Masaki OGINO , Tomoko OHASHI , Toshihiro IMAEDA , Ikuo FUJIMORI , Yasuhiro TSUKIMI , Masami YAMADA , Kenichiro SHIMOKAWA , Takeshi WAKABAYASHI , Masataka MURAKAMI , Makoto FUSHIMI , Tomohiro OKAWA , Jinichi YONEMORI , Tomohiro OHASHI , Hideo SUZUKI , Hironobu MAEZAKI , Ayumu SATO , Yasutomi ASANO , Steve SWANN
IPC分类号： C07D491/048 , A61K31/4355 , A61P1/10
摘要： The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
-
5.发明申请公开(公告)号：US20180162850A1
公开(公告)日：2018-06-14
申请号：US15735418
申请日：2016-06-23
发明人： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Jinichi YONEMORI , Takuto KOJIMA
IPC分类号： C07D413/14 , C07D413/10 , C07D265/22 , C07D417/10 , C07F7/08 , C07D491/107 , A61P25/28
CPC分类号： C07D265/22 , A61P25/28 , C07B2200/07 , C07D413/04 , C07D413/06 , C07D413/10 , C07D413/14 , C07D417/06 , C07D417/10 , C07D471/04 , C07D491/107 , C07F7/02 , C07F7/0814
摘要： The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
-
公开(公告)号：US20220340527A1
公开(公告)日：2022-10-27
申请号：US17754118
申请日：2020-09-25
发明人： Yuya OGURO , Makoto KAMATA , Shuhei IKEDA , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Shigemitsu MATSUMOTO , Hirotaka KAMITANI , Takaharu HIRAYAMA , Toshio TANAKA , Hiroshi BANNO , Nobuyuki TAKAKURA , Jinichi YONEMORI , Takuya FUJIMOTO
IPC分类号： C07D211/04 , C07D237/08 , C07D239/26 , C07D405/02
摘要： Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
-
公开(公告)号：US20190135799A1
公开(公告)日：2019-05-09
申请号：US16049359
申请日：2018-07-30
发明人： Masahiro ITO , Hideyuki SUGIYAMA , Osamu KUBO , Fumiaki KIKUCHI , Takeshi YASUI , Keiko KAKEGAWA , Zenichi IKEDA , Tohru MIYAZAKI , Yasuyoshi ARIKAWA , Tomohiro OKAWA , Jinichi YONEMORI , Akinori TOITA , Takuto KOJIMA , Yasutomi ASANO , Ayumu SATO , Hironobu MAEZAKI , Shinobu SASAKI , Hironori KOKUBO , Misaki HOMMA , Minoru SASAKI , Yasuhiro IMAEDA
IPC分类号： C07D413/14 , C07D471/04 , A61P25/28 , C07D413/04 , C07D417/14
CPC分类号： C07D413/14 , A61P25/28 , C07D413/04 , C07D417/14 , C07D471/04 , C07D487/04
摘要： The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
公开(公告)号：US20190083467A1
公开(公告)日：2019-03-21
申请号：US16083295
申请日：2017-03-09
发明人： Masaki OGINO , Eiji KIMURA , Shinkichi SUZUKI , Kouji FUJI , Tomohiro OHASHI , Makoto FUSHIMI , Kei MASUDA , Tatsuki KOIKE , Takeshi WAKABAYASHI , Jinichi YONEMORI , Masami YAMADA
IPC分类号： A61K31/4192 , A61K31/4155 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/28
摘要： Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.
-
公开(公告)号：US20180303841A1
公开(公告)日：2018-10-25
申请号：US15769295
申请日：2016-10-19
发明人： Takahiro SUGIMOTO , Shinkichi SUZUKI , Hiroki SAKAMOTO , Masami YAMADA , Minoru NAKAMURA , Makoto KAMATA , Kenichiro SHIMOKAWA , Masaki OGINO , Eiji KIMURA , Masataka MURAKAMI , Takuto KOJIMA , Jinichi YONEMORI
CPC分类号： A61K31/53 , A61K31/517 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/28 , C07D239/88 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/10 , C07D405/14
摘要： The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
-
公开(公告)号：US20180155333A1
公开(公告)日：2018-06-07
申请号：US15568644
申请日：2016-04-22
发明人： Taku KAMEI , Yasuyoshi ARIKAWA , Tomohiro OHASHI , Toshihiro IMAEDA , Ikuo FUJIMORI , Takashi MIKI , Jinichi YONEMORI , Yuya OGURO , Takahiro SUGIMOTO , Masaki SETO , Goushi NISHIDA , Makoto KAMATA , Hiroshi IMOTO
IPC分类号： C07D413/14 , C07D413/04 , C07D417/14 , C07D409/14 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30
CPC分类号： C07D413/14 , A61K31/553 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , C07D409/14 , C07D413/04 , C07D417/14
摘要： The present invention provide a compound having an orexin receptor antagonistic activity, which is expected to be useful as medicaments such as agents for the prophylaxis or treatment of sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.043 秒)
